What is NDC 72205-247?

72205-247 is the product NDC for Dexrazoxane, Dexrazoxane hydrochloride 250 mg/25mL injection, powder, lyophilized, for solution, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Dexrazoxane?

10 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Dexrazoxane NDC 72205-247 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-247Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0247Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-247-01	7220502470172205024701	1 VIAL, SINGLE-DOSE in 1 CARTON (72205-247-01) / 25 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 9, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dexrazoxane
Generic name (nonproprietary): dexrazoxane
Active ingredients: Dexrazoxane hydrochloride — 250 mg/25mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Novadoz Pharmaceuticals LLCNDC labeler code 72205
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216748
Marketing start: Mar 26, 2025
Listing expires: Dec 31, 2027
Identifiers: Product ID 72205-247_bdcb7617-046b-4db9-94ba-b10102565868SPL ID bdcb7617-046b-4db9-94ba-b10102565868SPL set ID a7c01089-85f5-40aa-b679-f53a425b4d68RxCUI 1736585, 1736590UNII 5346058Q7SUPC 0372205248014, 0372205247017
Pharmacologic class: Cytoprotective Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472205024701 followed by a unit qualifier and the quantity

Package 72205-0247-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2025.

Indications (excerpt from the label)

Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ]. Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72205-247

What is NDC 72205-247?: 72205-247 is the product NDC for Dexrazoxane, Dexrazoxane hydrochloride 250 mg/25mL injection, powder, lyophilized, for solution, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Dexrazoxane.
What is the active ingredient?: Dexrazoxane hydrochloride.
Who is the labeler?: Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Dexrazoxane?: 10 other product NDCs are listed under this name. See all Dexrazoxane NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Dexrazoxane NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Dexrazoxane	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Novadoz Pharmaceuticals LLC	72205-248	72205-0248-01
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Almaject, Inc.	72611-716	72611-0716-72
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 250 mg/25mL	Injection, Powder, Lyophilized, For solutionIntravenous	Fosun Pharma USA Inc.	72266-235	72266-0235-01
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 250 mg/25mL	Injection, Powder, Lyophilized, For solutionIntravenous	Gland Pharma Limited	68083-388	68083-0388-01
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Fosun Pharma USA Inc.	72266-101	72266-0101-01
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Gland Pharma Limited	68083-195	68083-0195-01
Dexrazoxane	—	Kit	Eugia US LLC	55150-434	55150-0434-02
Dexrazoxane	—	Kit	Eugia US LLC	55150-437	55150-0437-01
Dexrazoxane	Dexrazoxane hydrochloride 250 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9247	00143-9247-01
Dexrazoxane	Dexrazoxane hydrochloride 500 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9248	00143-9248-01

Other NDCs under ANDA 216748

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216748
Product	Strength	Form · route	Labeler	Product NDC
Dexrazoxane	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Novadoz Pharmaceuticals LLC	72205-248